Bevacizumab 1 — Class II drug recall D-0003-2026
Terminated recall by RC Outsourcing, LLC, reported 2025-10-15, distributed nationwide. Lack of assurance of sterility.
| Recall number | D-0003-2026 |
|---|---|
| Product type | Drug |
| Classification | Class II |
| Status | Terminated |
| Voluntary or mandated | Voluntary |
| Recalling firm | RC Outsourcing, LLC, Lowellville, OH, United States |
| Recall initiated | 2025-09-22 |
| Classified | 2025-10-06 |
| Reported by FDA | 2025-10-15 |
| Terminated | 2026-01-05 |
| Distributed | Nationwide (US) |
| Quantity | 2,669 syringes |
| Reason classes | sterility |
| Lot numbers | 20250708-768A26, 20250715-944DF2, 20250722-55C603, 20250722-5DC113 |
| Expiration dates | 2025-10-06, 2025-10-13, 2025-10-20 |
Product
Bevacizumab 1.75 mg/0.07 mL - 0.25 mL syringe, Intravitreal, 0.07 mL Total Volume, Rx Only, Hospital/Office Use Only, Refrigerate, RC Outsourcing LLC, Lowellville, OH 44436.
Reason for recall
Lack of assurance of sterility.
Machine access
This record, with every extracted code, the verbatim FDA record and provenance, is available from the recall API: GET https://api.data.aroqon.com/v1/recalls/D-0003-2026. Look up any UPC, UDI, NDC or lot with /v1/recalls/lookup?code=…. API docs · free and paid keys.
Source: U.S. Food and Drug Administration enforcement report via openFDA (CC0). Structured by Data Foundry (recall-structuring@2); last changed 2026-09-26. Not affiliated with or endorsed by FDA. Not medical or legal advice.